Nilotinib (Tasigna) for chonic myeloid leukemia: Health Canada evaluation

Information from Health Canada issued October 14, 2008 about the recently approval of nilotinib (Tasugna) On September 9, 2008, Health Canada issued a Notice of Compliance under the Notice of Compliance with Conditions (NOC/c) Policy to Novartis Pharmaceuticals Canada Inc. for the drug product Tasigna*. The product was authorized under the NOC/c Policy on the […]

Recomendations for the use of erlotinib (Tarceva) in patients with liver disease

Letter dated December 12, 2008 published on the Health Canada website on erlotinib adverse effects: Dear Health Care Professional, Hoffmann-La Roche Limited, in consultation with Health Canada would like to inform prescribers of important new safety information regarding the use of TARCEVA┬« (erlotinib) in patients with moderate hepatic impairment and advanced solid tumors. TARCEVA is […]